Company news

HanchorBio Inc. news

Latest news releases, newest first.

View company

HanchorBio Announces U.S. FDA Clearance of IND Application for HCB303, a Next-Generation Trispecific Immunotherapy

October 5, 2026

HanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit

September 9, 2026

HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership

July 8, 2026